COR Investors, You Need to Know These Facts Today.

By Chris Stiles • Wednesday, September 18 15:09 • Permanent Link

Large-cap Health Care company Cencora has moved -2.1% so far today on a volume of 1,344,966, compared to its average of 1,432,198. In contrast, the S&P 500 index moved -0.0%.

Cencora trades -12.73% away from its average analyst target price of $263.12 per share. The 15 analysts following the stock have set target prices ranging from $240.0 to $284.0, and on average have given Cencora a rating of buy.

If you are considering an investment in COR, you'll want to know the following:

Cencora's current price is 680.0% above its Graham number of $29.44, which implies that at its current valuation it does not offer a margin of safety
Cencora has moved 28.3% over the last year, and the S&P 500 logged a change of 28.0%
Based on its trailing earnings per share of 9.22, Cencora has a trailing 12 month Price to Earnings (P/E) ratio of 24.9 while the S&P 500 average is 28.21
COR has a forward P/E ratio of 15.5 based on its forward 12 month price to earnings (EPS) of $14.83 per share
The company has a price to earnings growth (PEG) ratio of 1.62 — a number near or below 1 signifying that Cencora is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 48.9 compared to its sector average of 3.69
Cencora, Inc. sources and distributes pharmaceutical products.
Based in Conshohocken, the company has 46,000 full time employees and a market cap of $45.01 Billion. Cencora currently returns an annual dividend yield of 0.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.